GO
Loading...

Boston Scientific Corp

More

  • Market Wrap: Stocks Slip Mostly On Weak Economic Report Thursday, 21 Dec 2006 | 4:53 PM ET

    Sellers outnumbered buyers on Wall Street after multiple reports signaled a slowdown in economic growth. CNBC's "Closing Bell" team sorted through the details.

  • CNBC's Schacknow: Breaking News Can Break A Producer Thursday, 21 Dec 2006 | 1:23 PM ET

    As The Stomach Turns:  Ah, the pressure of producing breaking news. I’ve done it enough times, yet I always find the monthly Philadelphia Fed report nerve wracking...

  • Boston Scientific has landed an exclusive contract to provide drug-coated stents to the Cleveland Clinic, one of the nation's most prominent cardiology centers, CNBC pharmaceuticals reporter Mike Huckman has learned.

  • CNBC's Huckman: Stent Battle Escalates Thursday, 21 Dec 2006 | 10:08 AM ET

    Within the last few hours CNBC's Pharmaceuticals Reporter Mike Huckman broke the news that Boston Scientific has locked up a huge account, but at what price?

  • Analyst: Christmas Isn't Over For Markets Monday, 11 Dec 2006 | 9:55 AM ET

    For traders, Christmas came early this year. A strong U.S. jobs report Friday and a rebound in the U.S. dollar have kicked up a bit of a "Santa Claus rally" in the markets. And at least one analyst says there are more gifts under the tree. Phil Dow, director of equity strategy at RBC Dain Rauscher, wouldn’t be surprised if we saw an additional percent or two before the year is through.

  • Update On FDA Panel: No Change On Stent Labels Friday, 8 Dec 2006 | 4:09 PM ET
    FDA

    As we've been writing--CNBC pharmaceuticals reporter Mike Huckman has been reporting from Gaithersburg, Md--where the U.S. Food and Drug Administration has convened a panel to decide the fate of drug-coated stents. Johnson & Johnson and Boston Scientific – the two major producers of stents – have been eagerly awaiting a decision.

  • Greetings from the Gaithersburg, Maryland Hilton! That's where the FDA is holding the advisory committee meeting on the safety of drug-coated stents. For less high-profile FDA meetings this hotel and the Holiday Inn across the street (the FDA alternates between them) are just fine. But for a big meeting like this one the venue is way too small.

  • Drug-coated stents that buttress the arteries are safe when used as directed, health advisers say, even though the risks they may pose to the majority of patients with the devices remains an open question

  • Late Word on Stents--And Friday on cnbc.com Thursday, 7 Dec 2006 | 3:47 PM ET

    There's late word from CNBC's Mike Huckman. He reported in "Closing Bell' that the FDA stent conference came out in support of drug-coated stents. There had been concerns the drug-coated stents caused blood clots--and the metal stents did not. But the FDA says the proof is inconclusive.

  • Drug-coated stents that prop open the arteries of about 3 million people in the U.S. don't increase the risk of heart attack or death when used as labeled but may put patients at risk for blood clots, health advisers said Thursday.

  • FDA And Stents: Which Ones Are Safe? Thursday, 7 Dec 2006 | 1:39 PM ET
    FDA

    The U.S. Federal Drug Administration is right now weighing in on the heated debate over drug coated stents versus metal ones. Stents are implanted in patients to stop heart attacks. They're looking into evidence that drug-coated stents-- may lead to dangerous blood clots. It's a huge concern that's effecting millions of heart patients. It's also effecting the $5 billion dollar drug-coated stent industry.

Most Popular Video

Tuesday, 15 Apr 2014 | 4:07 PM ET

"Yahoo's core business is still limping along," says Colin Gillis, BGC Financial, while providing instant reaction to Yahoo's quarterly numbers. "Shark Tank" investor Kevin O'Leary and "The Profit's" Marcus Lemonis weigh in.

Tuesday, 15 Apr 2014 | 11:31 PM ET

John Sculley, former Apple CEO and Managing Partner at Inflexionpoint, discusses his company's acquisitions in Singapore and India.

Tuesday, 15 Apr 2014 | 11:14 PM ET

Will Oswald, Global Head of FICC Research at Standard Chartered, says Beijing has the tools to guide its economy to a soft landing.